Vivo Capital LLC Takes Position in DBV Technologies S.A. $DBVT

Key Points

• Vivo Capital LLC bought a new position of 1,054,506 shares in DBV Technologies worth about $9.66 million, now owning roughly 3.85% of the company and making DBV its 18th largest holding (about 1.0% of Vivo's portfolio).
• DBV is a clinical-stage biopharma (notably developing Viaskin Peanut, which completed Phase 3) with a market cap near $660M; analyst sentiment is mixed but the consensus is a "Moderate Buy" with an average target of $20.81.

Vivo Capital LLC bought a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,054,506 shares of the company's stock, valued at approximately $9,659,000. DBV Technologies makes up approximately 1.0% of Vivo Capital LLC's investment portfolio, making the stock its 18th largest holding. Vivo Capital LLC owned about 3.85% of DBV Technologies as of its most recent SEC filing.

Separately, Nan Fung Trinity HK Ltd. purchased a new stake in DBV Technologies during the 2nd quarter worth $340,000. 71.74% of the stock is owned by institutional investors and hedge funds.

DBV Technologies Stock Performance

NASDAQ DBVT opened at $16.98 on Tuesday. DBV Technologies S.A. has a one year low of $2.74 and a one year high of $18.00. The company has a 50-day simple moving average of $14.21 and a 200-day simple moving average of $11.17. The firm has a market capitalization of $660.35 million, a PE ratio of -3.28 and a beta of -1.10.

Analyst Ratings Changes

DBVT has been the subject of several recent analyst reports. HC Wainwright restated a "buy" rating and set a $20.00 target price (up from $16.00) on shares of DBV Technologies in a research note on Wednesday, October 29th. Zacks Research upgraded DBV Technologies from a "strong sell" rating to a "hold" rating in a research note on Monday, September 29th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of DBV Technologies in a research report on Monday, December 1st. Wall Street Zen upgraded DBV Technologies from a "sell" rating to a "hold" rating in a research note on Friday, November 28th. Finally, Guggenheim began coverage on shares of DBV Technologies in a research note on Wednesday, December 3rd. They issued a "buy" rating and a $35.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $20.81.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

Want to see what other hedge funds are holding DBVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DBV Technologies S.A. (NASDAQ:DBVT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.